Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics (APGE)
NASDAQ:APGE
Total Valuation
Apogee Therapeutics has a market cap or net worth of $5.37B. The enterprise value is $1.82B.
Market Cap$5.37B
Enterprise Value$1.82B
Share Statistics
Apogee Therapeutics has 54,833,588 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,833,588
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Apogee Therapeutics’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -29.64%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-29.64%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-929.32K
Employee Count196
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Apogee Therapeutics is ―. Apogee Therapeutics’s PEG ratio is -0.14.
PE Ratio―
PS Ratio0.00
PB Ratio3.49
Price to Fair Value3.49
Price to FCF-14.51
Price to Operating Cash Flow-15.90
PEG Ratio-0.14
Income Statement
In the last 12 months, Apogee Therapeutics had revenue of 0.00 and earned -182.15M in profits. Earnings per share was -3.30.
Revenue0.00
Gross Profit0.00
Operating Income-216.87M
Pretax Income-182.13M
Net Income-182.15M
EBITDA-216.68M
Earnings Per Share (EPS)-3.30
Cash Flow
In the last 12 months, operating cash flow was -232.47M and capital expenditures -5.08M, giving a free cash flow of -237.56M billion.
Operating Cash Flow-232.47M
Free Cash Flow-237.56M
Free Cash Flow per Share-4.33
Dividends & Yields
Apogee Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change64.62%
50-Day Moving Average63.88
200-Day Moving Average44.81
Relative Strength Index (RSI)71.57
Average Volume (3m)792.04K
Important Dates
Apogee Therapeutics upcoming earnings date is Mar 10, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 10, 2026
Ex-Dividend Date―
Financial Position
Apogee Therapeutics as a current ratio of 18.55, with Debt / Equity ratio of 1.68%
Current Ratio18.55
Quick Ratio18.55
Debt to Market Cap<0.01
Net Debt to EBITDA0.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Apogee Therapeutics has paid 18.00K in taxes.
Income Tax18.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Apogee Therapeutics EV to EBITDA ratio is -10.94, with an EV/FCF ratio of -13.75.
EV to Sales0.00
EV to EBITDA-10.94
EV to Free Cash Flow-13.75
EV to Operating Cash Flow-13.85
Balance Sheet
Apogee Therapeutics has $527.29M in cash and marketable securities with $9.85M in debt, giving a net cash position of $517.44M billion.
Cash & Marketable Securities$527.29M
Total Debt$9.85M
Net Cash$517.44M
Net Cash Per Share$9.44
Tangible Book Value Per Share$12.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Apogee Therapeutics is $96.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$96.50
Price Target Upside24.76% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast-58.35%